Siemens to acquire a clinical laboratory diagnostics company and to sell automobile supplier business

2006/6/30　日本経済新聞夕刊 　　　　　　

シーメンス　バイエル診断薬買収

　独電機大手のシーメンスは２９日、医薬・化学大手バイエルの診断薬事業を買収すると発表した。金額は約４２億ユーロ(約６２００億円)。シーメンスは医療機関の検査・分析機器に強みがあるバイエルの事業買収で、ＣＴスキャンなど大型機器に注力する自社の医療機器事業を強化する。
　独禁当局の承認後、シーメンスは来年６月をめどにバイエルの事業を買収し、自社の医療機器事業に統合する。バイエルの診断薬事業の売上高は約１４億ユーロで、従業員数は約５千人。主に免疫や血液などの検査・分析機器を手掛ける。シーメンスは今月、通信インフラ機器事業で、通信機大手のノキア(フィンランド)と事業統合を決めるなど、収益事業への選択と集中を急いでいる。昨年就任したクラインフェルト社長は、医療機器を重点事業に位置づける。

2006/6/29 Siemens

Siemens to acquire Bayer Diagnostics arm
Medical Solutions Group further expands position in key high-growth molecular diagnostics market
http://www.siemens.com/index.jsp?sdc_p=fmls5uo1388841ni1079175pcz3&sdc_bcpath=1327899.s_5,&sdc_sid=17121076599&

Siemens has signed an agreement with Bayer to acquire the chemical and pharmaceutical company's Diagnostics Division. The acquisition will enable Siemens Medical Solutions (Med) to expand its position in the high-growth molecular diagnostics market. At the end of April, Siemens announced the planned acquisition of Diagnostic Products Corporation (DPC) in the U.S., a leading company in immunodiagnostics 免疫診断. The purchase price for Bayer Diagnostics - which had sales of Euro1.4 billion and a double-digit EBITDA margin in fiscal 2005 - is roughly Euro 4.2 billion.

“Demographic change is greatly increasing global demand for healthcare services and thereby generating excellent growth opportunities for Siemens,” explained Dr. Klaus Kleinfeld, Siemens President and CEO. ”The acquisition of Bayer Diagnostics is part of our targeted strategy to create the healthcare industry's first integrated diagnostics company by combining the entire imaging diagnostics, laboratory diagnostics and clinical IT value chain under one roof.” Kleinfeld also noted that this acquisition, which is subject to regulatory approval, is - like other purchases in the last few quarters - further proof that Siemens is rigorously focusing its portfolio on promising growth fields.

The company strengthened its position in molecular in-vivo diagnostics last year through the acquisition of CTI, delivering increased capabilities in the development and manufacture of positron emission tomography (PET) systems that can be used, for example, in the diagnosis of cancer and Alzheimer's disease, in addition to advanced development of new molecular contrast agents and pharmaceutical tracers.

January 1, 2007

Acquisition of Bayer's Diagnostic Division Finalized:
New Business - "Siemens Medical Solutions Diagnostics" - founded in the United States

The acquisition of Bayer Healthcare's diagnostic division by Siemens Medical Solutions has been completed. Bayer Diagnostics and Diagnostic Products Corporation (DPC), acquired in July 2006, were merged into a single business unit on January 1, 2007. The new entity, "Siemens Medical Solutions Diagnostics," is a wholly owned subsidiary of Siemens Medical Solutions USA, Inc. and employs more than 8,000 people worldwide. Siemens Medical Solutions Diagnostics, headquartered in Tarrytown, N.Y. and Los Angeles, CA, holds a No. 2 position in the worldwide immunodiagnostics market.

Bayer 2006/6/29

Bayer to sell diagnostics business to Siemens for EUR 4.2 billion
　HealthCare strategy being systematically implemented
　Bayer Diabetes Care Division and Schering contrast agents business not affected
　Decision not driven by financing of Schering acquisition

The Bayer Group plans to sell the Diagnostics Division of Bayer HealthCare to Siemens AG, Munich, Germany, for EUR 4.2 billion. The divestment was approved today by the Bayer Supervisory Board. “This decision is fully in line with our strategy for systematically aligning our health care business. We are concentrating on pharmaceuticals for both humans and animals, and products that can be promoted directly to patients,” explained Bayer AG Management Board Chairman Werner Wenning
The systems business of the Diagnostics Division, with its emphasis on hardware, IT networking and comprehensive equipment service, is subject to different success factors than the other Bayer HealthCare divisions.

The consumer-influenced Diabetes 糖尿病 Care Division is not affected by the transaction, nor is the contrast agents Ｘ線造影剤 (diagnostic imaging) business of Schering AG, which will form an important part of the future Bayer Schering Pharma AG.

Sales of Bayer HealthCare Diagnostics rose in 2005 by 8.4 percent to EUR 1.4 billion. The division employs more than 5,000 people worldwide. It offers an extensive portfolio of in-vitro diagnostic products for evaluating and monitoring the therapy of numerous diseases, including cardiovascular disorders, kidney diseases, infections, cancer and diabetes. The business units are Laboratory Testing, including the ADVIA Centaur^® and Centaur^® CP, ADVIA^® Clinical Chemistry, ADVIA LabCell^® and WorkCell^® Automation, ADVIA^® Hematology and Clinitek^® Atlas systems; Near Patient Testing, with its Rapidpoint^®, Rapidlab^®, RapidComm^TM and Clinitek^® brands; and Molecular Testing, with its Trugene^® and Versant^® lines of tests and systems.

Bayer HealthCare AG is one of the world's leading innovative companies in the health care and medical products industry. In 2005, this Bayer subgroup had sales of about EUR 9.4 billion. Bayer HealthCare employs approximately 33,800 people worldwide.

The company combines the activities of the Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals divisions. The Pharmaceuticals and Biological Products divisions were combined effective January 1, 2006. The new Pharmaceuticals Division comprises the Hematology/Cardiology, Oncology, and Primary Care business units.

Our aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. These products enhance well-being and quality of life by diagnosing, preventing and treating disease.

---

シーメンス旭メディテック株式会社

ドイツのシーメンスと旭化成工業の合弁企業。CT,MRI,血管撮影装置などの大型画像診断装置を主力ろする。2002年には超音波日門を吸収している。
設立：1979年４月６日
資本金:20億円
事業内容:画像診断装置など医療用機械器具の開発、製造、修理、保守、リース、輸出入　

---

シーメンス (Siemens AG) は、ドイツのバイエルン州ミュンヘンに本社を置く世界的な電気機器、電子機器の製造会社。1847年12月12日に、ヴェルナー・フォン・ジーメンス(Werner von Siemens) によってベルリンに創業された電信機製造会社、ジーメンス・ウント・ハルシュケ(Telegraphen-Bauanstalt von Siemens & Halske ) に端を発する。後にジーメンス・ハルスケ電車会社に発展し、世界で最初の電車を製造し、1881年に営業運転を開始した。

日本への進出は比較的早く、1861年(文久元年)に江戸幕府に電信機を納入している。1914年(大正3年)には、軍需品の納入を巡る海軍高官への贈賄事件、いわゆる「シーメンス事件」が発覚し、これによって当時の山本権兵衛内閣が総辞職に追い込まれた。

現在の日本では情報通信、電力、交通、医療などの各分野でその名が知られており、特に鉄道車両の制御装置（発車・停止寸前時の音の変化が音階に聞こえる特徴を持ったVVVFインバータ装置で鉄道ファンには有名）や磁気共鳴画像(MRI)装置、補聴器などで大きく市場を占有している。シーメンス製の携帯電話機は世界的にはよく知られているが、日本で採用しているPDC方式に対応した製品は生産していない。

Products & Systems

Angiography 血管検査方法
Fluoroscopy 蛍光透視システム
Magnetic Resonance 磁気共鳴(MR)
Molecular Imaging 細胞レベルの微細な機能変化をも発見する核医学診断装置。
Surgery　C 型のアームがついた X 線装置
Urology　泌尿器科システムと診察台
Computed Tomography　SOMATOM Sensation、新構成で放射線科の新しい可能性を開拓
IT Solutions　ヘルスケアに関するIT統合ソリューション
Mammography　乳がんの管理
Oncology Care　放射線腫瘍ソリューション
Radiography　放射線画像システム
Ultrasound　超音波診断装置

2006/4

Siemens to acquire Diagnostic Products Corporation
Siemens Medical Solutions enters the in-vitro diagnostics market
http://www.medical.siemens.com/webapp/wcs/stores/servlet/PressReleaseView?storeId=10001&langId=-11&catalogId=-11&catTree=100005,13839,17709&pageId=74203

Siemens and Diagnostic Products Corporation (DPC) announced today that they have entered into a merger agreement under which Siemens will acquire DPC for approximately $1.86 billion. DPC is one of the global leaders in immunodiagnostics, focusing on developing, manufacturing and distributing automated body fluid analyzers and tests, such as those related to cancer and cardiac disease, as well as hormone and allergy conditions. Through its presence in more than 100 countries, DPC offers comprehensive immunodiagnostic solutions to hospitals, clinics and laboratories across the globe.

Diagnostic Products Corporation, founded in 1971, is a leader in the global in vitro diagnostics market. DPC's product offering includes the widely accepted IMMULITEB. series of immunoassay systems, more than 75 immunoassays and an expanding menu of essential specific allergens and allergy panels that are run just like other immunoassays. DPC also designs and manufactures automated laboratory instrumentation and automation solutions that provide fast, accurate results while enabling our customers to do "more with less" in a leaner laboratory. DPCbs combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. In fiscal 2005 (December 31), DPC reported sales of $481 million and income from operations of $96 million. Additional information can be found at DPCbs website at www.dpcweb.com

2005/3/15

Siemens To Acquire CTI Molecular Imaging, Inc.
Acquisition Expands Molecular Imaging Competencies of Siemens Medical Solutions - Joint Press Release by Siemens und CTI Molecular Imaging

Siemens and CTI Molecular Imaging, Inc. (Nasdaq: CTMI) announced today that they have entered into a merger agreement under which Siemens will acquire CTI. The acquisition will include all the businesses of CTI Molecular Imaging, Inc., including CTI PET Systems, PETNET Solutions, CTI Mirada Solutions, CTI Molecular Technologies and CTI Concorde Microsystems. Under the terms of the agreement, Siemens Medical Solutions USA, Inc., will commence a cash tender offer within ten business days to acquire all of the outstanding shares of CTI stock at a price of $20.50 per share. Following the completion of the tender offer, any remaining shares of CTI stock will be acquired in a merger at the same price per share. The board of directors of each company has approved the agreement. The transaction is subject to customary regulatory approvals and other customary closing conditions, and is expected to close in the second quarter of 2005. The transaction has a value of approximately $1 billion.

CTI Molecular Imaging was established in 1983, focusing on positron emission tomography (PET) and molecular imaging and later extended its business into research, development and the distribution of PET tracers and probes. CTI PET Systems (CPS) was formed in 1987 as a joint venture between CTI and Siemens to combine CTI’s expertise in PET technology with Siemens’ global distribution network.

CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology for detection and treatment of cancer, neurological disorders and cardiac disease. In fiscal year 2004 (September 30), CTI reported sales of $402 million and income from operations of $58 million. Additional information is available at http://www.ctimi.com.

About PET and PET/CT:
PET images the biology of diseases at the molecular level, often before anatomic changes are visible or, in some cases, before symptoms appear. Diseases are biological processes and it is these processes that PET examines. PET/CT is an imaging technology that combines the biological examination of patients by PET with the CT images of the body's structural detail. PET/CT technology improves the diagnostic accuracy and treatment management of patients by providing surgeons, radiation oncologists and other physicians with precise anatomical landmarks associated with the disease condition as determined by PET. PET's whole-body imaging capability helps physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed. Recent published clinical trials have shown that in a wide array of cancers, the use of PET has caused the treatment to be changed for 15 to 50% of patients, depending on the specific clinical question. In addition, PET and PET/CT provide both the patient and their physician with a degree of certainty that is often unavailable through other imaging methods.

2006年6月19日

ノキアとシーメンス、コミュニケーション・サービス・プロバイダー事業を統合 - 固定・モバイル コンバージェンスの新しいグローバル ネットワークリーダーに

ノキアとシーメンスは本日、ノキアのネットワークス事業部とシーメンスのキャリア関連ビジネスを新会社に統合し、ノキア・シーメンス・ネットワークス（Nokia Siemens Networks）という名称の下に新会社を設立すると発表しました。新会社は50-50の出資比率の合弁会社で、固定およびモバイル・ネットワーク・インフラストラクチャとサービスの重要な成長分野において、確固たる地位を持つグローバル・リーダー企業を生み出すものです。

Jul 25, 2007 Siemens 　　　　　　　　　　　　　　　シーメンス　バイエル診断薬買収

Siemens to acquire Dade Behring
　　Medical Solutions Group becomes leader in the growing Diagnostics Market

Siemens has signed a merger agreement with US-based Dade Behring, Inc., a leading clinical laboratory diagnostics company. Siemens intends to acquire all outstanding shares of Dade Behring by submitting a cash offer to the Dade Behring shareholders of US$77 per common share. The planned acquisition has a total transaction volume of approximately US$7 billion (roughly Euro 5 billion). Closing is expected in the second quarter of fiscal year 2008. Completion of the merger is subject to receipt of regulatory approvals and other customary closing conditions.

By further strengthening its presence in clinical laboratory diagnostics, Siemens Medical Solutions continues to pursue its vision to become the global leader in full-service diagnostics, offering imaging diagnostics, clinical laboratory diagnostics and healthcare IT solutions - from a single source and along the entire value chain. "The planned acquisition of Dade Behring complements our current capabilities and offers us the unique opportunity to create an unparalleled portfolio of products and services, and become world market leader in comprehensive clinical laboratory diagnostics," highlighted Erich R. Reinhardt.

About Dade Behring, Inc.
With 2006 revenue of more than US$1.7 billion, Dade Behring offers a wide range of products, systems and services designed to meet the day-to-day needs of clinical laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the Internet at www.dadebehring.com.

Dade Behring 　http://www.dadebehring.com/

With 2006 revenue of nearly $1.7 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics臨床検査薬. It offers a wide range of products, systems and services designed to meet the day-to-day needs of clinical laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients.

The businesses from which Dade Behring was formed have been innovators in clinical diagnostics for more than a century. Dade Behring was created in 1997 through the merger of Dade International and the Behring Diagnostics unit of Hoechst AG. Earlier, these companies had combined the diagnostics businesses of the DuPont Company, Syva Company and Baxter Healthcare. Now, Dade Behring ranks as the sixth largest diagnostics company in the world.

The company has four core product lines: Chemistry/Immunochemistry免疫化学, Hemostasis止血, Microbiology 細菌学　and Infectious Disease感染病 Diagnostics.

Dade Behring combines the strengths of Behring Diagnostics and Dade International, as well as the diagnostics businesses of the DuPont Company, Syva, MicroScan and American Hospital Supply Corporation.

1994 - A group of investors buys Baxter's diagnostics business and establishes Dade International.
　　　　　　1980 - American Hospital Supply acquires MicroScan Inc
　　　　　　1985 - Baxter International acquires American Hospital Supply
1995 - Hoechst AG establishes Behring Diagnostics as a stand-alone business and also acquires Syva Company.
1996 - Dade International purchases DuPont's diagnostics business.
1997 - Dade International and Behring Diagnostics combine operations to form Dade Behring.
2005 - Dade Behring acquires a portion of India-based Ranbaxy Laboratories' diagnostics business

---

Jul 25, 2007 Siemens

Siemens sells automobile supplier business to Continental for Euro11.4 billion

Siemens AG is signing an agreement with Continental AG, Hanover, Germany, to sell its entire stake in Siemens VDO Automotive AG (SV). The price is Euro11.4 billion. The closing of the transaction is subject to approval by the responsible antitrust authorities and other closing conditions and is expected in the current calendar year. Peter Löscher, President and CEO of Siemens AG, said: "We have reached an outstanding result. We have carefully evaluated all options for SV and chose the best perspectives for the employees, customers, and our investors." Preparations for the planned IPO of SV will be terminated.

The sale of SV supports the goals set in the company’s Fit for 2010 program. These goals include a focused further development of the business portfolio in the three application fields of Energy and Environmental Care, Automation and Control/Industrial and Public Infrastructures, and Healthcare. “We have already made major investments in these fields in the recent past,” commented Löscher. “As we pursue this course, we must be even more oriented to growth and margins, and keep an eye on the capital-intensity of our businesses. We will make Siemens more focused, less complex, and faster.”

　

Siemens VDO Automotive AG, a Group of Siemens AG, is one of the world's leading suppliers of electronics and mechatronics for the automotive industry.

---

Fit for 2010 program

“Fit For 2010” program is a seamless continuation of our successful “Fit4More” program.

Performance　　　　　　　　 　　　　　　　　　　　　　　　　　
　・Optimize capital efficiency with ROCE (return on capital employed) of 　〉14-16%
　・Attain cash conversion rate of "1-growth rate"
　・Sustain 2xGDP growth
　・Achieve new margin range

Portfolio　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　
　・Build on outstrenghts in
　　　・Energy & Enviconmental Care
　　　・Automation & Control, Industrial & Public Infrastructures
　　　・Healthcare
　・IPO of Siemens VDO ・・・・今回の売却で、IPOは取り止め

People Excellence　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　
　・Develop talent globally
　・Strenghen leadership development
　・Attain high performance culture
　・Strenghen expert careers

Operational Excellence
　・Execute Siemens Management System (proved buy top ) with focus on
　　　・Innovation
　　　・Customer focus
　　　・Gloval Competitiveness

Corporate Responsibility
　・Achieve best-in-class in
　　　・Corporate Governance
　　　・Compliance
　　　・Climate protection
　　　・Corporate Citizenship

Presentation (2007/7/25) 　　Accelerating growth and creating value
http://www.siemens.com/Daten/siecom/HQ/CC/Internet/Investor_Relations/WORKAREA/ir_ed/templatedata/English/file/binary/Q3_Analyst_Call_CEO_1457267.pdf

Dade Behring の吸収合併により、In-vitro 診断薬分野でNo.1の地位を獲得する。

Founded in 1969, Shared Medical Systems Corporation has over 30 years of network computing experience, operating the industry's largest Information Services Center (ISC) and Health Information Network for application hosting, e-commerce, enterprise systems management, and managed Internet services. SMS specializes in information solutions for hospitals, provides process and structural consulting, application services and manages IT infrastructures. As the premier Application Service Provider (ASP) in healthcare, SMS's ISC operates health applications for over 1,000 health providers with connections to over 400,000 customer workstations, and processes 80 million transactions each day.